vTv Therapeutics Inc. VTVT
30.21
(0.52)
(1.69%)
as of 25 Sep
- Market cap
- $121.5M
- P/E
- 0.0×
Follow VTVT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 13.00 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | 53.76 | — | — | |
P/B ratio |
— | 5.47 | — | — | |
Price to Tangible BV |
— | 5.47 | — | — | |
EV/Sales |
— | 10.41 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (37.86) | — | — | |
EV/FCF |
— | (37.54) | — | — | |
Quick Ratio |
12.35 | 14.25 | 13.39 | 9.69 | |
Current Ratio |
12.48 | 14.36 | 13.54 | 9.79 | |
Net Debt/EBITDA |
6.22 | (4.22) | 11.28 | 9.21 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.58 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.38 | 1.30 | 0.60 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 24.37% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 12.48% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 3.77% | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.18 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (1.61%) | — | — | |
Free Cash Flow Yield |
— | (2.13%) | — | — | |
Revenue per Share |
0.00 | 2.97 | 0.00 | 0.00 | |
Operating CF per Share |
(0.92) | 0.74 | (1.10) | (0.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.92) | 0.74 | (1.10) | (0.65) | |
Cash per Share |
6.98 | 7.90 | 10.56 | 12.23 | |
Shareholders Equity per Share |
6.34 | 7.25 | 7.65 | 8.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.34 | 7.25 | 7.65 | 8.76 | |
Free Cash Flow |
(11.44) | 9.15 | (9.25) | (5.22) | |
Working Capital |
80.57 | 91.93 | 83.25 | 89.29 | |
Net Current Asset Value |
78.63 | 89.95 | 64.43 | 70.51 | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
— | 0.00 | — | — | |
Net Profit Margin |
0.00% | 65.51% | 0.00% | 0.00% | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
6.10 | 5.51 | 5.79 | 8.01 | |
Average Assets |
57.02 | 65.42 | 64.08 | 71.33 | |
Average Common Equity |
40.52 | 49.43 | 39.37 | 44.23 |
Columns are period end dates